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Abstract. DNA methylation might be the earliest somatic 
genome changes in prostate cancer that also play an important 
role in the process of tumor invasion, growth and metastasis. 
In recent years, several inhibitors of DNA methyltransferases 
(DNMTis) have been developed and evaluated in pre-clinical 
models and in clinical trials. While these compounds are 
effective in the treatment of hematological conditions, clinical 
trials in solid tumors and in prostate cancer have shown 
limited or no efficacy. This may be attributed to inappropriate 
dose regimens leading to toxicity-related adverse events. As 
with other anti-target compounds, one of the obstacles encoun-
tered with DNMTis in prostate cancer could be the inability to 
select patients for the clinical studies as well as the inability 
to monitor the efficacy of the drug if not the conclusion of 
the study. Primary cultures derived from human prostatic 
tissues harvested from patients with benign prostatic hyper-
plasia (BPH) and prostate cancer (PCa) as well as neoplastic 
and non-neoplastic prostate cell lines were tested for DNMT 
expression/activity and to monitor azacitidine molecular 
efficacy. We observed that in primary cultures the levels 
of DNMT activity as well as the protein levels of DNMT1, 
DNMT3a and DNMT3b were higher in cultures derived from 
PCa compared to BPH tissue samples and significantly higher 
in cultures derived from PCa with Gleason scores ≥7 compared 
to those observed in cultures derived from Gleason scores <7. 
In addition, DNMT activity as well as DNMT1, DNMT3a and 
DNMT3b levels were higher in PCa cell lines compared to 
their non-neoplastic counterparts. Although DNMT activity 
was higher in high tumorigenic/aggressive PCa cell lines 
compared to low tumorigenic/aggressive cell lines, only the 
levels of DNMT3a and DNMT3b were significantly higher 
in the first group of cells, suggesting that DNMT1 activity is 
related to the transition to non-neoplastic versus neoplastic 
phenotype whereas the de novo methylation enzymes were 
mainly related to progression. Nevertheless, the comparison 
in the more aggressive PC3 cell derivatives (PC3-LN4 cells) 
also possessed higher levels of DNMT1 compared to PC3 and 
PC3M from which these cells were derived. Collectively, our 
results confirm previous data on the increased methylation 
in more aggressive tumors supporting the use of DNMTis 
in advanced prostate cancer. In addition, since glutathione 
S-transferase-π (GSTP1) was re-expressed or its protein levels 
were increased after treatment with non-toxic azacitidine 
doses and since GSTP1 can easily be measured in patient sera, 
the monitoring of this protein may aide in the evaluation of 
therapy in future clinical trials.
Introduction
Prostate cancer (PCa) is one of the most commonly diagnosed 
male cancers in Western countries and is a leading cause 
of cancer mortality (1). Radical prostatectomy and/or local 
radiotherapy are the standard treatment for patients with 
organ-confined PCa. However, in 15-30% of these patients, 
PCa progresses as metastatic disease (2).
Epigenetic inactivation of genes in cancer cells is largely 
based on transcriptional silencing by aberrant CpG meth-
ylation of CpG-rich promoter regions. Disruption in the DNA 
methylation machinery resulting in global hypomethylation 
and regional hypermethylation is well documented in most 
types of cancer affecting gene activity. Genes with unmethyl-
ated CpG islands are competent for regulated transcription, 
responding to signaling cues by recruiting trans-activating 
factors that modify nucleosome and chromatin structure, 
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using histone acetyltransferases and histone methyltransfer-
ases to promote transcript synthesis by RNA polymerases. By 
contrast, genes with methylated CpG islands tend to be incom-
petent for expression, tightly wound around nucleosomes in a 
repressive chromatin structure maintained by histone deacety-
lases (HDACs) and other enzymes. Thus, somatic increases in 
CpG island methylation in cancer cells have been associated 
with gene silencing and heterochromatinization. Bedford 
and van Helden in 1987 (3) observed that DNA methylation 
levels were significantly lower in prostates with benign pros-
tatic hyperplasia (BPH) and metastatic tumors. By contrast, 
non-metastatic prostate tumor DNA had a 5-methylcytosine 
content essentially the same as in normal tissue.
Prostatic carcinogenesis has been associated with the loss 
of glutathione S-transferase-π (GSTP1) by methylation evident 
in some 5-10% of proliferative inflammatory atrophy (PIA) 
lesions, the earliest prostate cancer precursors, and in <70% of 
prostatic intraepithelial neoplasia lesions (4,5). Human pros-
tate cancer cells devoid of GSTP1 better activate heterocyclic 
amine carcinogens, such as those found in overcooked meats, 
to mutagenic species than cells capable of GSTP1 expression 
(6). GSTP1 silencing early during the pathogenesis of prostate 
cancer, with the resultant loss of enzymatic protection against 
reactive chemical species, may offer an explanation for the 
well-known sensitivity of human prostatic carcinogenesis to 
dietary and lifestyle habits (7-9).
Three major enzymes are responsible for DNA methyla-
tion in eukaryotes: DNMT1, DNMT3a and DNMT3b (10-12). 
DNMT1 has been implicated primarily in the maintenance of 
methylation patterns that occurs during cellular replication and 
it preferentially methylates hemi-methylated DNA. It has been 
the most extensively studied maintenance methyltransferase 
and is abundant in tumor cells and tissues. DNMT3a and 
DNMT3b are known to be de novo methylators of CpG sites, 
which have higher methyltransferase activity for unmethylated 
DNA than DNMT1 and can contribute to de novo methylation 
during embryogenesis and tumorigenesis. In the transgenic 
mouse model of PCa (TRAMP), DNMT expression increases 
during the progressive stages of PCa (13,14). The DNMT 
inhibitor 5-azacytidine (5-aza-CR) as well as its deoxy- 
derivative, 5-aza-2'-deoxycytidine (5-aza-CdR), prevents 
prostatic disease progression and the development of lymph 
node metastases in this model (15). Demethylating agents have 
been shown to be effective in the treatment of myelodysplastic 
syndromes (16). While in vitro experiments and animal models 
have shown that 5-aza-CR has antitumor activities in several 
types of cancer, including prostate cancer (17-21), clinical 
trials with 5-aza-CR (Vidaza) or its deoxy derivative 5-aza-
CdR (decitabine) for the treatment of solid tumors have shown 
no significant effects due to the high side-effects (22,23). The 
majority of genes activated by demethylating agents, such 
as Rb, p16, E-cadherin, APC, VHL, retinoic acid receptor β, 
BRCA1 and DLC-1, are, however, tumor-suppressor genes and 
are related to chemo-resistance (21,24) in different types of 
cancer cells. We previously reported that prostate tumor cells 
may acquire androgen independence upon hormone therapy 
through epigenetic mechanisms involving modifications of 
DNMT expression and activity both in patients treated with 
bicalutamide as neoadjuvant hormone therapy (NHT) and 
in vitro systems (25-27). In addition, it has been shown that 
upon castration, the TRAMP mouse develops ‘castration-
resistant’ prostate tumors similar to those seen with the 
recurrence of human prostate tumor growth after androgen-
deprivation therapy. Treatment with 5-aza-CdR was found to 
increase survival of TRAMP mice and delayed prostate cancer 
progression, including the recurrence of prostate tumor growth 
after castration (12,13). We also demonstrated that azacitidine 
was able to amplify or restore bicalutamide treatment (26,27) 
or chemotherapy (21). In the present study, we analyzed the 
expression of DNMT1, DNMT3a and DNMT3b in primary 
culture from BPH and PCa human tissue samples as well as in 
neoplastic and non-neoplastic prostate epithelial cells.
Materials and methods
Reagents. All the materials for tissue culture were purchased 
from Hyclone (Cramlington, NE, USA). Plasticware was 
obtained from Nunc (Roskilde, Denmark). Azacitidine 
(Vidaza®) was obtained in collaboration with Celgene Corp. 
(Summit, NJ, USA). Antibodies against cytokeratin 8 (K8), 5 
(K5) and 14 (K14) and PSA, vimentin (VMNT) and AMACR 
were purchased from Santa Cruz Biotechnology (Santa Cruz, 
CA, USA). Anti-DNMT1, DNMT3a and DNMT3b antibodies 
were purchased from BioCarta (Hamburg, Germany). GSPT1 
monoclonal antibody (ALX-804-510) was purchased from 
Enzo Life Sciences (Vinci-Biochem Srl Florence, Italy).
Cell lines. We used non-tumor prostate epithelial cell lines 
[BPH-1, RWPE-1 and EPN (28)] and 9 PCa cells lines [CWR22 
(29), 22Rv1 (29), LAPC-4 (30), LNCaP, VCaP (31), DuCaP (31), 
C4-2B (32), DU145 and PC3]. PC3 and LNCaP cell derivatives 
(PCM, PC3-Pro4, PC3-LN4, LNCaP-Pro5 and LNCaP-Ln5) 
were kindly provided by Dr I.J. Fidler and Dr C.A. Pettaway 
(33). Cells were cultured as previously described.
Primary tumor cultures. The primary tumor cultures of 
PCa were established from specimens of consenting patients 
undergoing radical prostatectomy. A wedge-shaped specimen 
of the fresh prostate was removed within 1 h of surgery. 
Frozen sections of a part of this tissue were used to confirm 
the prostatic origin and for diagnosis. We analysed 10 tissues 
harvested from BPH and 40 tissues derived from patients with 
clinically localized tumors surgically treated with prostatec-
tomy as previously described (34-36). Tissue samples were 
minced and cultured in DMEM.
Preparation of cell lysates and western blot analysis. Cells 
were washed with cold PBS and immediately lysed with 1 ml 
lysis buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 10% gly - 
cerol, 1% Triton X-100, 1 mM EDTA, 1 mM EGTA, 50 mM 
NaF, 1 mM sodium orthovanadate, 30 mM p-nitrophenyl 
phosphate, 10 mM sodium pyrophosphate, 1 mM phenylmeth-
ylsulfonyl fluoride, 10 µg/ml aprotinin and 10 µg/ml leupeptin). 
The nuclear extracts were collected as described: cells were 
scraped in 1 ml PBS-EDTA and centrifuged at 3,000 rpm. 
Pellets were resuspended in 1 ml harvest buffer containing 
10 mM HEPES, pH 7.9, 50 mM NaCl, 0.5 M sucrose, 0.1 mM 
EDTA and 0.5% Triton X-100 and incubated on ice for 5 min. 
Cells were pelleted at 1,000 rpm with a table top swinging 
microfuge, washed and resuspended in 1 ml of 10 mM HEPES, 
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pH 7.9 containing 10 mM KCl, 0.1 mM EDTA and 0.1 mM 
EGTA. Lysates were electrophoresed in 7% SDS-PAGE and 
separated proteins were transferred to nitrocellulose and 
probed with the appropriate antibodies using the conditions 
recommended by the suppliers.
DNA methyltransferase activity assay. DNMT activity was 
evaluated by a colorimetric EpiQuik DNMT Activity Assay 
kit (BioVision, Mountain View, CA, USA) in nuclear extracts 
of cells treated with 5-Aza-CR according to the manufacturer's 
instructions.
Statistical analysis. Continuous variables were summarized 
as mean and standard deviation (SD) or as median and 95% CI 
for the median. For continuous variables not normally distrib-
uted, statistical comparisons between control and treated 
groups were established using the Kruskal-Wallis tests. For 
continuous variables normally distributed, statistical compari-
sons between control and treated groups were established by 
the ANOVA test or by the Student's t-test for unpaired data (for 
two comparisons).
Results
Characterization of primary epithelial cancer cell cultures 
was performed as previously described (43-45). Organoids 
and small cell aggregates similar to acini attached within 2-5 
days of primary culture and small outgrowths appeared with 
cells forming polygonal colonies of various grades of archi-
tecture. A morphological aspect of three prostate epithelial 
cultures with small polygonal cells containing dark granules 
and large polyclonal cells are shown in Fig. 1. Some cells 
formed small compact isles and acquired a wavy pattern. 
Moreover, we observed that some cells formed irregular 
colonies showing senescent signs such as multinuclear 
aspect and flattened epithelial sheets with a final tendency 
to intersect. Cells were positive for K18, which are typical 
of prostatic lumenal cells, and for K14, typical of basal cells 
with variable levels of K5, typical for intermediated/ampli-
fying cells. Low expression of AR and PSA characterized 
our primary cell cultures whereas AMACR was present in 
~70% of primary cultures. Only AMACR positive cultures 
were used in our study. In Fig. 1D we show the expres-
sion of the above-mentioned markers in AMACR positive 
cultures. A densitometric analysis of the GSTP1 expression 
(Fig. 1E) allowed us to observe that 10/10 (100%) of BPH 
cultures were GSTP1 positive whereas 62.5% (25/40) of PCa 
cultures showed GSTP1 protein. Following randomization in 
two groups based on the Gleason score, 5/25 (20%) cultures 
containing low/absent levels of GSTP1 were grouped in the 
Gleason score <7 whereas 10/15 (66.7%) with low/absent 
levels of GSTP1 were in the Gleason score ≥7 group. In addi-
tion, we showed that 5-aza-CR was able to re-express GSTP1 
in human primary cell cultures (Fig. 2), suggesting that 
GSTP1 may be considered a potentially useful biomarker for 
the methylation status of prostate cancer cells, which is in 
accordance with previous reports (11-14).
DNMT activity and expression in primary cultures derived 
from BPH and PCa tissue samples. We also demonstrated that 
Figure 1. (A-C) Three examples of prostate epithelial cultures with small polygonal cells with dark granules. (A) Large polyclonal cells, (B) irregular colonies, 
(C) shows senescent signs such as multinuclear aspect and flattened epithelial sheets with a final tendency to intersect. (D) Cells were positive for K18 and 
K14. Low expression of AR and PSA was present. Only AMACR positive cultures were used in our study. (E) GSTP1 demonstrated by western blot analysis 
and densitometric evaluation. G, Gleason score.
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DNMT activity was higher in primary cultures derived from 
PCa compared to BPH tissue samples. In Fig. 3A we show 
single values of DNMT activity in representative BPH (10/10), 
PCa Gleason <7 (10/25) and PCa Gleason ≥7 (10/15). The 
differences between the values of DNMT activity observed 
in BPH-derived cultures (0.68±0.30 mU/mg of protein) 
were significantly lower compared with those observed in 
PCa-derived cultures (1.90±0.81 mU/mg of protein, P<0.001). 
DNMT activity was significantly higher in cultures derived 
from Gleason score ≥7 (2.31±0.70 mU/mg of protein) compared 
to those observed in Gleason score <7 derived cultures 
(1.49±0.72 mU/mg of protein, P<0.005). The evaluation of 
the levels of DNMT1 also shows that PCa-derived cultures 
resulted in higher levels of protein compared to BPH cultures. 
In Fig. 3B we showed single values of DNMT1 protein expres-
sion in representative BPH (10/10), PCa Gleason <7 (10/25) and 
PCa Gleason ≥7 (10/15). The differences between the values 
of arbitrary densitometric units for DNMT1 protein observed 
in BPH-derived cultures (0.56±0.27 ADU) were significantly 
lower compared with those observed in PCa-derived cultures 
(1.09±0.33 ADU, P<0.001). The DNMT1 protein levels were 
significantly higher in cultures derived from Gleason score ≥7 
(1.31±0.32 ADU) compared to those observed in Gleason score 
<7 derived cultures (0.86±0.13 ADU, P<0.001). Evaluation of 
Figure 2. GSTP1 was increased in positive cultures (BPH #4 and #9 or PCa #6 and #7) and restored in very low/absent (PCa #10) cultures. The levels of 
increment is proportional to the amount of DNT activity of single cultures.
Figure 3. DNMT activity and expression in primary cultures derived from BPH and PCa tissue samples. Single values of DNMT activity in representative 
BPH (10/10), PCa Gleason <7 (10/25) and PCa Gleason ≥7 (10/15) are shown. (A) DNMT activity was higher in primary cultures derived from PCa compared 
to BPH tissue samples. DNMT activity was also significantly higher in cultures derived from Gleason score ≥7 compared to those observed in Gleason 
score <7-derived cultures. (B) DNMT1 expression levels were higher in PCa-derived cultures compared to BPH cultures and significantly higher in cultures 
derived from Gleason score ≥7 compared to those observed in Gleason score <7-derived cultures. (C) DNMT3a expression levels were higher in PCa-derived 
compared to BPH-derived cultures and similar in cultures derived from Gleason score ≥7 compared to those observed in Gleason score <7-derived cultures. 
(D) DNMT3b protein levels were higher in PCa-derived compared to BPH-derived cultures and statistically lower in cultures derived from Gleason score ≥7 
compared to those observed in Gleason score <7-derived cultures. 
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the levels of DNMT3a also shows that PCa-derived cultures 
resulted in higher levels of protein compared to BPH cultures. 
In Fig. 3C we show single values of DNMT1 protein expres-
sion in representative BPH (10/10), PCa Gleason <7 (10/25) and 
PCa Gleason ≥7 (10/15). The differences between the values of 
arbitrary densitometric units for DNMT3a protein observed 
in BPH-derived cultures (0.25±0.14 ADU) were significantly 
lower compared with those observed in PCa-derived cultures 
(0.83±0.30 ADU, P<0.001). The DNMT3a protein levels 
were similar in cultures derived from Gleason score ≥7 
(0.82±0.25 ADU) compared to those observed in Gleason 
score <7-derived cultures (0.84±0.36 ADU, NS). Evaluation 
of the levels of DNMT3b also show that PCa-derived cultures 
produced higher levels of protein compared to BPH cultures. 
In Fig. 3D we show single values of DNMT3b protein expres-
sion in representative BPH (10/10), PCa Gleason <7 (10/25) and 
PCa Gleason ≥7 (10/15). The differences between the values of 
arbitrary densitometric units for DNMT3b protein observed 
in BPH-derived cultures (0.06±0.02 ADU) were significantly 
lower compared with those observed in PCa-derived cultures 
(0.43±0.17 ADU, P<0.001). The DNMT3a protein levels were 
statistically lower in cultures derived from Gleason score ≥7 
(0.34±0.14 ADU) compared to those observed in Gleason 
score <7-derived cultures (0.52±0.16 ADU, NS).
Higher DNMT activity and expression are observed in more 
aggressive PCa cell lines. Next, we analyzed DNMT activity 
and DNMT expression in different prostate cancer cell 
lines with different tumorigenic and metastatic capacities. 
We demonstrated that DNMT activity (Fig. 4A), as well as 
the expression of DNMT1 (Fig. 4B), DNMT3a (Fig. 4C) 
and DNMT3b (Fig. 4D) were higher in neoplastic vs. non-
neoplastic prostate epithelial cell lines and this was in 
agreement with previous findings (41). Conversely, only 
DNMT1 expression was higher in aggressive/androgen-
independent (PC3, DU145 and 22Rv1 cell lines) compared 
to low tumorigenic/androgen-dependent (CWR22, LAPC4, 
LNCaP, DuCaP and VCaP) prostate cancer cells. The levels 
of DNMT3a and DNMT3b were higher in more tumorigenic 
cells compared to low tumorigenic cells but the differences 
were not significant. The comparison in PC3 and LNCaP cell 
derivatives possessing higher metastatic potential shows that 
DNMT1, DNMT3A and DNMT3b were significantly higher 
(Fig. 5A) in more metastatic PC3-LN4 and LNCaP-Ln5 cell 
derivatives compared to parental cells. 
GSTP1 may be re-expressed or up-modulated by azacitidine. 
GSTP1 was expressed at high levels only in RWPE-1 and 
BPH1 cells, EPN cells expressed low levels of this protein 
whereas all prostatic cancer cell lines analyzed were negative. 
However, azacitidine was able to increase GSTP1 expression 
in EPN cells and to restore protein expression in PCa cell lines. 
In Fig. 5B we show the effects of aza-CR on 3 representative 
cell lines (EPN, LAPC-4 and PC3).
Figure 4. Higher DNMT activity and expression were observed in more aggressive PCa cell lines. (A) DNMT activity as well as the expression of DNMT1 (B), 
DNMT3a (C) and DNMT3b (D) were higher in neoplastic vs. non-neoplastic prostate epithelial cell lines. Conversely, only DNMT1 expression levels were 
higher in aggressive/androgen-independent (PC3, DU145 and 22Rv1) compared to low tumorigenic/androgen-dependent (CWR22, LAPC4, LNCaP, DuCaP 
and VCaP) prostate cancer cells. The levels of DNMT3a and DNMT3b were higher in more tumorigenic cells compared to low tumorigenic cells but the 
differences were not significant. 
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Discussion
In recent years, several inhibitors of DNMTs have been devel-
oped and evaluated in pre-clinical models and in clinical trials. 
Among these, 5-azacytidine (5-aza-CR, Vidaza) and 5-aza-
deoxycytidine (5-aza-dC, decitabine) have received Food and 
Drug Administration (FDA) approval for the treatment of 
myelodysplastic syndromes (MDS) (37,38), and these agents 
and others are being tried alone and in combination with other 
drugs as cancer therapeutic agents. One major disadvantage 
of Vidaza or decitabine is that they are nucleoside analogs, 
whose mechanism of action involves incorporation of the 
aza-modified base into DNA during DNA synthesis with 
subsequent covalent trapping of the DNMTs. As with other 
nucleoside analogs, these drugs can have significant cytotox-
icity and can lead to major adverse effects when administered 
to patients. While these compounds are effective in the treat-
ment of hematologic conditions, clinical trials in solid tumors 
and in prostate cancer have shown limited or no efficacy 
(22,25). This may be attributed to inappropriate dose regi-
mens leading to the above-mentioned toxicity-related adverse 
events. However, as with several anti-target compounds one of 
the possible obstacles encountered with Vidaza or decitabine, 
could be the inability to select patients to be enrolled in the 
clinical studies as well as the inability to monitor the efficacy 
of the drug if not the conclusion of the study. Based on our 
findings from the study as well as from a previous report (39), 
we propose monitoring the expression of DNMT1, DNMT3a 
and DNMT3b in prostate tissues obtained from biopsy of 
radical prostatectomy, and evaluating the levels of GSTP 
before and during the treatment, taking into consideration 
that GSTP1 (a molecular hallmark of human prostate cancer, 
the expression of which epigenetic silencing reduces during 
prostate carcinogenesis and progression) may be re-expressed 
after 5-aza-CR treatment and is easily measured in a patient's 
serum and urine (40-42) or circulating tumor cells. In this 
study, we demonstrated that DNMT activity and the levels of 
DNMT1, DNMT3a and DNMT3b were significantly higher in 
primary cultures derived from PCa compared to BPH. Greater 
differences in the protein levels were, however, observed for 
DNMT3a and DNMT3b. Next, we demonstrated that DNMT 
activity and DNMT1 enzyme expression were not statistically 
higher in cultures derived from Gleason score ≥7 compared to 
those observed in cultures derived from lower Gleason scores, 
whereas the levels of DNMT3a and DNMT3b were statisti-
cally higher in Gleason scores >7. This is in agreement with 
findings previously observed in human PCa tissue in which 
we demonstrated that DNMT expression, particularly for 
DNMT3a and DNMT3b levels, varied with tumor differen-
tiation (34). We then demonstrated that DNMT activity was 
higher in aggressive androgen-independent compared to low 
tumorigenic androgen-dependent prostate cancer cells and 
this was in agreement with previous results (43). In addition, 
we demonstrated that GSTP1 may be a target for azacitidine 
treatment since exposure of human prostate cancer cells to 
1 mM aza-CR for 1-7 days caused a concentration- and time-
dependent re-expression of GSTP1, which was correlated with 
DNMT inhibition. Taken together, our results support that 
GSTP1 may be considered a useful marker of DNMTi treat-
ment efficacy which will facilitate its use as a biomarker in 
future clinical trials. The ability to track efficacy of the drug 
using tissue biopsies or circulating tumor cells at earlier time-
points could greatly assist future clinical trials. In addition, 
GSTP1 has the potential to improve the assessment of drug 
efficacy, thus reducing both the duration and cost of a clinical 
trial, and, secondly, it may improve the welfare of patients in 
clinical trials by minimizing unnecessary exposure.
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